Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(14):1047; doi:10.1093/jnci/96.14.1047
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

© 2004 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

State-Mandated Reimbursement for Cancer Trial Participation

An often-cited barrier to enrollment in cancer clinical trials is payer reimbursement. Gross et al. (p. 1063) examined if state mandates ensuring coverage of routine medical care costs of cancer trial participants increased patient enrollment rates for National Cancer Institute–sponsored phase II and cooperative group phase III trials between 1996 and 2001. They compared enrollment of participants in four states that had enacted coverage policies in 1999 with enrollment in states without policies. After the state mandates were enacted in 1999, the authors found that phase II trial enrollment increased at a greater rate . . . [Full Text of this Article]

Lung Cancer Histologic Type in SEER vs. Independent Review

HAART, SIL, and HIV-Positive Women

Conventional vs. High-Dose Therapy for Breast Cancer

Quality of Life and Adherence in a Screening Trial

Breast-feeding, Breast Cancer, and BRCA Mutations